Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: Organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study

Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Suee Lee, Dae Ho Lee, Jong Ho Won, In Gyu Hwang, Min Kyoung Kim, Soon Il Lee, Yee Soo Chae, Deok Hwan Yang, Hye Jin Kang, Chul Won Choi, Jinny Park, Hyo Jung Kim, Jung Hye Kwon, Ho Sup Lee, Gyeong Won Lee, Hyeon Seok EomJae Yong Kwak, Won Sik Lee, Cheolwon Suh, Hyo Jin Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

According to a previous review, multiple mucosa-associated lymphoid tissue (MALT)-organs involving marginal zone B cell lymphomas (MZLs) are present in 10-30% of patients. However, the clinical features and specific relationships among involved organs are yet to be clearly identified. In this study, we conducted retrospective analyses of multiple MALT organs involving MZLs (MM-MZLs) to identify their clinical features, treatment, prognosis, and specific relationships among involved organs. For analysis, between June 1987 and June 2009, a total of 55 patients from 17 different institutions in Korea, all of whom were histologically diagnosed with MM-MZL, were included in this study. MM-MZL was defined as MZL involving more than 2 different MALT organs. Multiple involvements within one MALT organ (e.g. both side ocular lesions, multiple lung nodules, and multiple stomach lesions, etc.) were excluded from this study. The male/female ratio of the 55 patients was 41/14. The median age of our subjects was 59 years (range 30-82 years). MM-MZL without lymph node (LN) was detected only in 9 patients (36.2%). Bone marrow (BM) involvement was observed in 17 patients (30.9%). The most common site of involvement was the gastrointestinal (GI) tract (25 patients, 45.5%) followed by the lung (40%), Waldeyer's ring (WR) (27.3%), and ocular area (25.5%). Ocular MZLs were commonly accompanied with WR- or lung-MZLs. GI-MZLs were WR or GI-MZLs. Lung-MZLs were frequently observed with ocular and GI-MZLs. WR-MZLs were ocular or GI-MZLs. A total of 53 patients were treated, and 2 on watchful wait. As much as 48 patients received chemotherapy-based treatment. Among them, CR or PR was achieved in 38 patients (79.2%, 95% CI 67-91%). Median time to progression (TTP) was 2.3 years (95% CI 1.4-3.2 years). Cause-specific overall survival (OS) did not reach the median value. The 5-year OS rate was 84.9%. MM-MZLs tend to be an indolent disease, characterized by prolonged survival with frequent relapses. The majority of cases could be controlled effectively via chemotherapy-based treatment, and prolonged survival was achieved in those patients. The GI, lung, WR, and ocular area were commonly presented with other MALT site MZLs, and an organ-specific relationship appears to be relevant to MM-MZLs.

Original languageEnglish
Pages (from-to)510-517
Number of pages8
JournalInternational Journal of Hematology
Volume92
Issue number3
DOIs
Publication statusPublished - 2010 Oct 1

Fingerprint

Marginal Zone B-Cell Lymphoma
Lymphoid Tissue
Lymphoma
Mucous Membrane
Survival
Lung
Drug Therapy
Korea
Gastrointestinal Tract
Stomach
Therapeutics
Survival Rate
Lymph Nodes
Bone Marrow

Keywords

  • B cell lymphoma
  • Marginal zone
  • Mucosa-associated lymphoid tissues
  • Multiple

ASJC Scopus subject areas

  • Hematology

Cite this

Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma : Organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. / Oh, Sung Yong; Kim, Won Seog; Kim, Jin Seok; Kim, Seok Jin; Lee, Suee; Lee, Dae Ho; Won, Jong Ho; Hwang, In Gyu; Kim, Min Kyoung; Lee, Soon Il; Chae, Yee Soo; Yang, Deok Hwan; Kang, Hye Jin; Choi, Chul Won; Park, Jinny; Kim, Hyo Jung; Kwon, Jung Hye; Lee, Ho Sup; Lee, Gyeong Won; Eom, Hyeon Seok; Kwak, Jae Yong; Lee, Won Sik; Suh, Cheolwon; Kim, Hyo Jin.

In: International Journal of Hematology, Vol. 92, No. 3, 01.10.2010, p. 510-517.

Research output: Contribution to journalArticle

Oh, SY, Kim, WS, Kim, JS, Kim, SJ, Lee, S, Lee, DH, Won, JH, Hwang, IG, Kim, MK, Lee, SI, Chae, YS, Yang, DH, Kang, HJ, Choi, CW, Park, J, Kim, HJ, Kwon, JH, Lee, HS, Lee, GW, Eom, HS, Kwak, JY, Lee, WS, Suh, C & Kim, HJ 2010, 'Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: Organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study', International Journal of Hematology, vol. 92, no. 3, pp. 510-517. https://doi.org/10.1007/s12185-010-0680-z
Oh, Sung Yong ; Kim, Won Seog ; Kim, Jin Seok ; Kim, Seok Jin ; Lee, Suee ; Lee, Dae Ho ; Won, Jong Ho ; Hwang, In Gyu ; Kim, Min Kyoung ; Lee, Soon Il ; Chae, Yee Soo ; Yang, Deok Hwan ; Kang, Hye Jin ; Choi, Chul Won ; Park, Jinny ; Kim, Hyo Jung ; Kwon, Jung Hye ; Lee, Ho Sup ; Lee, Gyeong Won ; Eom, Hyeon Seok ; Kwak, Jae Yong ; Lee, Won Sik ; Suh, Cheolwon ; Kim, Hyo Jin. / Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma : Organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. In: International Journal of Hematology. 2010 ; Vol. 92, No. 3. pp. 510-517.
@article{cbe4993e78b84a1bae785d3e76bec599,
title = "Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: Organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study",
abstract = "According to a previous review, multiple mucosa-associated lymphoid tissue (MALT)-organs involving marginal zone B cell lymphomas (MZLs) are present in 10-30{\%} of patients. However, the clinical features and specific relationships among involved organs are yet to be clearly identified. In this study, we conducted retrospective analyses of multiple MALT organs involving MZLs (MM-MZLs) to identify their clinical features, treatment, prognosis, and specific relationships among involved organs. For analysis, between June 1987 and June 2009, a total of 55 patients from 17 different institutions in Korea, all of whom were histologically diagnosed with MM-MZL, were included in this study. MM-MZL was defined as MZL involving more than 2 different MALT organs. Multiple involvements within one MALT organ (e.g. both side ocular lesions, multiple lung nodules, and multiple stomach lesions, etc.) were excluded from this study. The male/female ratio of the 55 patients was 41/14. The median age of our subjects was 59 years (range 30-82 years). MM-MZL without lymph node (LN) was detected only in 9 patients (36.2{\%}). Bone marrow (BM) involvement was observed in 17 patients (30.9{\%}). The most common site of involvement was the gastrointestinal (GI) tract (25 patients, 45.5{\%}) followed by the lung (40{\%}), Waldeyer's ring (WR) (27.3{\%}), and ocular area (25.5{\%}). Ocular MZLs were commonly accompanied with WR- or lung-MZLs. GI-MZLs were WR or GI-MZLs. Lung-MZLs were frequently observed with ocular and GI-MZLs. WR-MZLs were ocular or GI-MZLs. A total of 53 patients were treated, and 2 on watchful wait. As much as 48 patients received chemotherapy-based treatment. Among them, CR or PR was achieved in 38 patients (79.2{\%}, 95{\%} CI 67-91{\%}). Median time to progression (TTP) was 2.3 years (95{\%} CI 1.4-3.2 years). Cause-specific overall survival (OS) did not reach the median value. The 5-year OS rate was 84.9{\%}. MM-MZLs tend to be an indolent disease, characterized by prolonged survival with frequent relapses. The majority of cases could be controlled effectively via chemotherapy-based treatment, and prolonged survival was achieved in those patients. The GI, lung, WR, and ocular area were commonly presented with other MALT site MZLs, and an organ-specific relationship appears to be relevant to MM-MZLs.",
keywords = "B cell lymphoma, Marginal zone, Mucosa-associated lymphoid tissues, Multiple",
author = "Oh, {Sung Yong} and Kim, {Won Seog} and Kim, {Jin Seok} and Kim, {Seok Jin} and Suee Lee and Lee, {Dae Ho} and Won, {Jong Ho} and Hwang, {In Gyu} and Kim, {Min Kyoung} and Lee, {Soon Il} and Chae, {Yee Soo} and Yang, {Deok Hwan} and Kang, {Hye Jin} and Choi, {Chul Won} and Jinny Park and Kim, {Hyo Jung} and Kwon, {Jung Hye} and Lee, {Ho Sup} and Lee, {Gyeong Won} and Eom, {Hyeon Seok} and Kwak, {Jae Yong} and Lee, {Won Sik} and Cheolwon Suh and Kim, {Hyo Jin}",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s12185-010-0680-z",
language = "English",
volume = "92",
pages = "510--517",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma

T2 - Organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study

AU - Oh, Sung Yong

AU - Kim, Won Seog

AU - Kim, Jin Seok

AU - Kim, Seok Jin

AU - Lee, Suee

AU - Lee, Dae Ho

AU - Won, Jong Ho

AU - Hwang, In Gyu

AU - Kim, Min Kyoung

AU - Lee, Soon Il

AU - Chae, Yee Soo

AU - Yang, Deok Hwan

AU - Kang, Hye Jin

AU - Choi, Chul Won

AU - Park, Jinny

AU - Kim, Hyo Jung

AU - Kwon, Jung Hye

AU - Lee, Ho Sup

AU - Lee, Gyeong Won

AU - Eom, Hyeon Seok

AU - Kwak, Jae Yong

AU - Lee, Won Sik

AU - Suh, Cheolwon

AU - Kim, Hyo Jin

PY - 2010/10/1

Y1 - 2010/10/1

N2 - According to a previous review, multiple mucosa-associated lymphoid tissue (MALT)-organs involving marginal zone B cell lymphomas (MZLs) are present in 10-30% of patients. However, the clinical features and specific relationships among involved organs are yet to be clearly identified. In this study, we conducted retrospective analyses of multiple MALT organs involving MZLs (MM-MZLs) to identify their clinical features, treatment, prognosis, and specific relationships among involved organs. For analysis, between June 1987 and June 2009, a total of 55 patients from 17 different institutions in Korea, all of whom were histologically diagnosed with MM-MZL, were included in this study. MM-MZL was defined as MZL involving more than 2 different MALT organs. Multiple involvements within one MALT organ (e.g. both side ocular lesions, multiple lung nodules, and multiple stomach lesions, etc.) were excluded from this study. The male/female ratio of the 55 patients was 41/14. The median age of our subjects was 59 years (range 30-82 years). MM-MZL without lymph node (LN) was detected only in 9 patients (36.2%). Bone marrow (BM) involvement was observed in 17 patients (30.9%). The most common site of involvement was the gastrointestinal (GI) tract (25 patients, 45.5%) followed by the lung (40%), Waldeyer's ring (WR) (27.3%), and ocular area (25.5%). Ocular MZLs were commonly accompanied with WR- or lung-MZLs. GI-MZLs were WR or GI-MZLs. Lung-MZLs were frequently observed with ocular and GI-MZLs. WR-MZLs were ocular or GI-MZLs. A total of 53 patients were treated, and 2 on watchful wait. As much as 48 patients received chemotherapy-based treatment. Among them, CR or PR was achieved in 38 patients (79.2%, 95% CI 67-91%). Median time to progression (TTP) was 2.3 years (95% CI 1.4-3.2 years). Cause-specific overall survival (OS) did not reach the median value. The 5-year OS rate was 84.9%. MM-MZLs tend to be an indolent disease, characterized by prolonged survival with frequent relapses. The majority of cases could be controlled effectively via chemotherapy-based treatment, and prolonged survival was achieved in those patients. The GI, lung, WR, and ocular area were commonly presented with other MALT site MZLs, and an organ-specific relationship appears to be relevant to MM-MZLs.

AB - According to a previous review, multiple mucosa-associated lymphoid tissue (MALT)-organs involving marginal zone B cell lymphomas (MZLs) are present in 10-30% of patients. However, the clinical features and specific relationships among involved organs are yet to be clearly identified. In this study, we conducted retrospective analyses of multiple MALT organs involving MZLs (MM-MZLs) to identify their clinical features, treatment, prognosis, and specific relationships among involved organs. For analysis, between June 1987 and June 2009, a total of 55 patients from 17 different institutions in Korea, all of whom were histologically diagnosed with MM-MZL, were included in this study. MM-MZL was defined as MZL involving more than 2 different MALT organs. Multiple involvements within one MALT organ (e.g. both side ocular lesions, multiple lung nodules, and multiple stomach lesions, etc.) were excluded from this study. The male/female ratio of the 55 patients was 41/14. The median age of our subjects was 59 years (range 30-82 years). MM-MZL without lymph node (LN) was detected only in 9 patients (36.2%). Bone marrow (BM) involvement was observed in 17 patients (30.9%). The most common site of involvement was the gastrointestinal (GI) tract (25 patients, 45.5%) followed by the lung (40%), Waldeyer's ring (WR) (27.3%), and ocular area (25.5%). Ocular MZLs were commonly accompanied with WR- or lung-MZLs. GI-MZLs were WR or GI-MZLs. Lung-MZLs were frequently observed with ocular and GI-MZLs. WR-MZLs were ocular or GI-MZLs. A total of 53 patients were treated, and 2 on watchful wait. As much as 48 patients received chemotherapy-based treatment. Among them, CR or PR was achieved in 38 patients (79.2%, 95% CI 67-91%). Median time to progression (TTP) was 2.3 years (95% CI 1.4-3.2 years). Cause-specific overall survival (OS) did not reach the median value. The 5-year OS rate was 84.9%. MM-MZLs tend to be an indolent disease, characterized by prolonged survival with frequent relapses. The majority of cases could be controlled effectively via chemotherapy-based treatment, and prolonged survival was achieved in those patients. The GI, lung, WR, and ocular area were commonly presented with other MALT site MZLs, and an organ-specific relationship appears to be relevant to MM-MZLs.

KW - B cell lymphoma

KW - Marginal zone

KW - Mucosa-associated lymphoid tissues

KW - Multiple

UR - http://www.scopus.com/inward/record.url?scp=78549251362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549251362&partnerID=8YFLogxK

U2 - 10.1007/s12185-010-0680-z

DO - 10.1007/s12185-010-0680-z

M3 - Article

C2 - 20838958

AN - SCOPUS:78549251362

VL - 92

SP - 510

EP - 517

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -